NCT05327010 2026-03-18
Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
13 trialsNCT01042379 2026-03-13
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT02693535 2026-02-13
TAPUR
American Society of Clinical Oncology
Phase 2 Recruiting
NCT04734730 2026-01-28
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
City of Hope Medical Center
Phase 2 Recruiting
NCT05873192 2025-12-23
Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06844383 2025-10-29
TALENT
Prostate Cancer Clinical Trials Consortium
Phase 2 Recruiting
NCT04678362 2025-09-22
TALASUR
Centre Francois Baclesse
Phase 2 Recruiting
NCT03990896 2025-08-07
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
Massachusetts General Hospital
Phase 2 Recruiting
NCT05071937 2025-06-22
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
University of Pittsburgh
Phase 2 Recruiting
NCT04892693 2025-04-17
Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency
Seoul National University Hospital
Phase 2 Recruiting
NCT06193525 2025-02-28
FUTURE
Erasmus Medical Center
Phase 2 Recruiting
NCT04819243 2025-01-03
Young-PALETTA
Samsung Medical Center
Phase 2 Recruiting
NCT05725200 2023-02-21
EVIDENT
Oslo University Hospital
Phase 2 Recruiting